Local Infusion

MYLOCALINFUSION.COM

ULTOMIRIS (RAVULIZUMAB-CWVZ) ORDER FORM

PATIENT INFORMATION

Patient Name: ______________________ DOB: __________

Mobile Number: ______________ Patient Weight: ______________

Allergies: ______________________

DIAGNOSIS (Provider must specify)

- ❑ Myasthenia Gravis (without acute exacerbation), ICD 10: G70.00
- ❑ Myasthenia Gravis with acute exacerbation, ICD 10: G70.01
- ❑ Paroxysmal Nocturnal Hemoglobinuria (PNH), ICD 10: D59.5
- ❑ Atypical Hemolytic Uremic Syndrome (aHUS), ICD 10: D59.3
- ❑ Neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive, ICD 10: D36.0
- ❑ Other: ______________

PROVIDER INFORMATION

Provider Name (print name): ______________________ Provider NPI: __________

Signature: ______________________ Date: __________

Contact Name: ______________ Phone: __________ Fax: __________

Email Address: ______________________

Prerequisites to treatment – ensure the following information is complete and attached with referral:

❑ Demographics ❑ Labs and tests supporting diagnosis ❑ Office/progress notes

PRE-MEDICATION (Not typically indicated)

- ❑ Acetaminophen (Tylenol) 500 mg PO
- ❑ Benadryl 25mg PO
- ❑ Famotidine 20 mg IV
- ❑ Cetirizine (Zyrtec) 10 mg PO
- ❑ Methylprednisolone (Solu-Medrol) 125 mg IVP
- ❑ Other: ______________ Dose: __________ Route: __________

MEDICATION

MEDICATION	DOSE	ROUTE	FREQUENCY
Ultomiris	❑ Pt weight 40-59kg: 2,400 mg on week 0 and 2, then 3,000 mg every 8 weeks ❑ Pt weight 60-99kg: 2,700 mg on Week 0 and 2, then 3,300mg every 8 weeks ❑ Pt weight 100 kg or greater: 3,000mg on Week 0 and 2, then 3,600mg every 8 weeks	❑ IV	❑ Week 0, 2 then every 8 weeks ❑ Every 8 weeks

❑ New Start Therapy ❑ Continuation of Therapy Date of last dose (if applicable): ______________

LABS / SPECIAL INSTRUCTIONS

FAX NUMBERS: ❑ CT: 203.433.0621 ❑ ME: 207.407.7272 ❑ NH: 603.217.5371 ❑ NJ: 201.581.4521

Order valid for 1 year from date of signature unless otherwise specified here: __________